patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

(foscarbidopa + foslevodopa)

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

indications

investigational

Parkinson's Disease

all catalysts(2)

approval · 2

News(0)

no news has mentioned this drug yet

brand

Vyalev

generic

(foscarbidopa + foslevodopa)

MOA

12.1 Mechanism of Action VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.

indication

Parkinson's Disease

phase

marketed

(foscarbidopa + foslevodopa)

indications

all catalysts(2)

News(0)

Patent cliff

patents (4)

FDA exclusivities (1)

Report a data issue

comments(0)

🐶 often sniffed alongside